정신분열병 환자의 골밀도 저하 위험요소에 대한 고찰：양성 및 음성 증후군 척도를 중심으로

키워드

참고문헌 (37)

1. World Health Organization, "Guideline for preclinical evaluation and clinical trial in osteoporosis" (1998), World Health Organization
2. Cooper GS, "Long-term effect of reproductive-age menstrual cycle patterns on peri- and postmenopausal fracture risk", AM J Epidemiol, 145, pp.804~809 (1997)
3. Gennari C, "Secondary osteoporosis", Aging, 10, pp.214~224 (1998)
4. Kleinberg DL, "Prolactin levels and adverse events in patients treated with risperidone", J Clin Psychopharmacol, 19, pp.57~61 (1999)
5. Wudarsky M, "Elevated prolactin in pediatric patients on typical and atypical antipsychotics", J Child Adolesc Psychopharmacol, 9, pp.239~245 (1999)
6. O'Keane V, "Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?", J Clin Psychopharmacol, 25, pp.26~31 (2005)
7. Kishimoto T, "Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineraldensity in male patients with schizophrenia", J Clin Psychiatry, 69, pp.385~391 (2008)
8. Abraham G, "Osteoporosis demonstrated by dual energy x-ray absorptiometry in chronic schizophrenic patients", Biol Psychiatry, 26, pp.41~54 (1996)
9. Howard L, "Risk of hip fracture in patients with a history of schizophrenia", Br J Psychiatry, 190, pp.129~134 (2007)
10. Kapur S, "Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia", Am J Psychiatry, 157, pp.514~520 (2000)
11. Naidoo U, "Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents", Psychoneuroendocrinology, 28, pp.97~108 (2003)
12. Naliato EC, "Prevalence of osteopenia in men with prolactinoma", J Endocrinol Invest, 28, pp.12~17 (2005)
13. Wyszogrodzka-Kucharska A, "Decrease in mineral bone density in schizophrenic patients treated with 2nd generation antipsychotics", Psychiatr Pol, 39, pp.1173~1184 (2005)
14. Meaney AM, "Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables", Schizophr Res, 93, pp.136~143 (2007)
15. 원승희, "만성 정신분열병 여성에서 고프로락틴혈증과 골밀도 및 골대사 표지의 상관", 생물치료정신의학, 12(2), pp.204~214 (2006), 대한생물치료정신의학회
16. Parfitt AM, "Quantum concept of bone remodeling and turnover: implications for the patho-genesis of osteoporosis", Calcif Tissue Int, 28, pp.1~5 (1979)
17. Nordin BE, "Nutrition, osteoporosis, and aging", Ann NY Acad Sci, 854, pp.336~351 (1998)
18. Kanis J, "Risk factors for hip fracture in men from southern Europe: the MEDOS study. Mediterranean Osteoporosis Study", Osteoporosis, 9, pp.45~54 (1999)
19. Misra M, "Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism", J Clin Psychiatry, 65, pp.1607~1618 (2004)
20. Halbreich U, "Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation", CNS Drugs, 21, pp.641~657 (2007)
21. Hummer M, "Osteoporosis in Patients With Schizophrenia", Am J Psychiatry, 162, pp.162~167 (2005)
22. Petty SJ, "Effect of antiepile-ptic medication on bone mineral measures", Neurology, 65, pp.1358~1365 (2005)
23. Haney EM, "Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men", Arch Intern Med, 167, pp.1246~1251 (2007)
24. Meaney AM, "Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia", Br J Psychiatry, 184, pp.503~508 (2004)
25. Becker D, "Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients", J Clin Psychiatry, 64, pp.761~766 (2003)
26. Roke Y, "Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects", J Child Adolesc Psychopharmacol, 19, pp.403~414 (2009)
27. Howes OD, "Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment", J ClinPsychopharmacol, 25, pp.259~261 (2005)
28. Abraham G, "Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study", Am J Psychiatry, 160, pp.1618~1620 (2003)
29. Bergemann N, "High bone turnover but normal bone mineral density in women suffering from schizophrenia", Psychol Med, 38, pp.1195~1201 (2008)
30. Acil AA, "The effects of physical exercises to mental state and quality of life in patients with schizophrenia", Health Nurs, 15, pp.808~815 (2008)
31. Falloon IR, "Persistent auditory hallucinations: coping mechanisms and implications for management", Psychol Med, 11, pp.329~339 (1981)
32. Carter DM, "Patients' strategies for coping with auditory hallucinations", J Nerv Ment Dis, 184, pp.159~164 (1996)
33. Karow A, "Subjective view of positive symptomsand quality of life in patients with schizophrenia", Psychiatr Prax, 35, pp.286~293 (2008)
34. Bozikas VP, "Community dysfunction in schizophrenia: rate-limiting factors", Prog Neuropsychopharmacol Biol Psychiatry, 30, pp.463~470 (2006)
35. Kulhara P, "Positive and negative subtypes of schizophrenia. A follow-up study from India", Schizophr Res, 3, pp.107~116 (1990)
36. Hori A, "Symptom classification of schizophrenia changes with the duration of illness", Acta Psychiatr Scand, 99, pp.447~452 (1999)
37. Jung DU, "Prevalence of bone mineral density loss in Korean patients with schizophrenia: a crosssectional study", J Clin Psychiatry, 67, pp.1391~1396 (2006)

관련 논문AI추천